19851-01-5

Basic information

• Product Name: 3-MORPHOLIN-4-YL-PROPIONALDEHYDE
• Synonyms: 3-MORPHOLIN-4-YL-PROPIONALDEHYDE;4-morpholinepropanal
• CAS NO: 19851-01-5
• Molecular Formula: C₇H₁₃NO₂
• Molecular Weight: 143.18
• Mol File: 19851-01-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 129-130 °C(Press: 10 Torr)
• Appearance: /
• Density: 1.023±0.06 g/cm3(Predicted)
• PKA: 6.66±0.10(Predicted)
• CAS DataBase Reference: 3-MORPHOLIN-4-YL-PROPIONALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-MORPHOLIN-4-YL-PROPIONALDEHYDE(19851-01-5)
• EPA Substance Registry System: 3-MORPHOLIN-4-YL-PROPIONALDEHYDE(19851-01-5)

Safety Data

• Hazardous Substances Data: 19851-01-5(Hazardous Substances Data)

Usage

General Description

3-Morpholin-4-yl-propionaldehyde is a chemical compound with the molecular formula C8H15NO2. It is a yellow liquid with a strong odor, and it is used in the manufacturing of various chemical products. It is commonly used as an intermediate in the production of pharmaceuticals, agrochemicals, and other organic compounds. It is also used as a fragrance ingredient in perfumes and personal care products. Additionally, it is used as a flavoring agent in the food industry. This chemical is considered to have low toxicity, but proper safety precautions should always be taken when handling it.

Upstream product

• 110-91-8 morpholine 
• 107-02-8 acrolein 
• 4441-30-9 3-morpholin-4-ylpropan-1-ol 

Downstream Products

• 1160360-60-0 3-tert-butyl-5-((4-fluorobenzyl)(3-morpholinopropyl)amino)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one 

Relevant articles and documents

Chroman-4-one- and chromone-based sirtuin 2 inhibitors with antiproliferative properties in cancer cells

Sirtuins (SIRTs) catalyze the NAD+-dependent deacetylation of Nε-acetyl lysines on various protein substrates. SIRTs are interesting drug targets as they are considered to be related to important pathologies such as inflammation and aging-associated diseases. We have previously shown that chroman-4-ones act as potent and selective inhibitors of SIRT2. Herein we report novel chroman-4-one and chromone-based SIRT2 inhibitors containing various heterofunctionalities to improve pharmacokinetic properties. The compounds retained both high SIRT2 selectivity and potent inhibitory activity. Two compounds were tested for their antiproliferative effects in breast cancer (MCF-7) and lung carcinoma (A549) cell lines. Both compounds showed antiproliferative effects correlating with their SIRT2 inhibition potency. They also increased the acetylation level of α-tubulin, indicating that SIRT2 is likely to be the target in cancer cells. A binding mode of the inhibitors that is consistent with the SAR data was proposed based on a homology model of SIRT2.